Introduction
============

Prolonged exposure of human skin to ultraviolet B (UVB) radiation (290--320 nm) induces clinical and histological alterations due to the onset of simultaneous destruction and repair ([@b1-etm-0-0-4626]). Environmental factors, such as solar light, may lead to extrinsic aging, which occurs due to dyspigmentation, telangiectasia and collagen degradation ([@b2-etm-0-0-4626],[@b3-etm-0-0-4626]). The pathogenesis of skin photoaging induced by UVB involves reactive oxygen species (ROS)-mediated inflammation ([@b4-etm-0-0-4626]--[@b6-etm-0-0-4626]), keratinocyte apoptosis ([@b7-etm-0-0-4626],[@b8-etm-0-0-4626]) and the degradation of matrix macromolecules by matrix metalloproteinases (MMPs) ([@b9-etm-0-0-4626]). Consequently, wrinkle formation, epidermal thickening ([@b10-etm-0-0-4626]), extracellular matrix (ECM) degradation-related water loss and skin dryness ([@b11-etm-0-0-4626]) all increase. Thus, it is important to reduce UVB-induced skin aging, as the maintenance of skin health against UVB exposure is directly associated with whole body health ([@b10-etm-0-0-4626],[@b12-etm-0-0-4626]).

ROS may be generated by UV irradiation and damage cellular lipids, proteins and DNA, resulting in the alteration and destruction of skin structures. This may result in the failure of the skin to function normally ([@b13-etm-0-0-4626]). UVB-induced ROS overproduction leads to an imbalance between ROS and antioxidant enzymes, as well as a reduction in glutathione (GSH) levels ([@b14-etm-0-0-4626],[@b15-etm-0-0-4626]). Furthermore, UVB exposure triggers the release of numerous cytokines that participate in the onset of cutaneous inflammation ([@b16-etm-0-0-4626],[@b17-etm-0-0-4626]). These molecules serve an important role in edema, which occurs as a result of vasodilation, the opening of interendothelial junctions and the separation of endothelial cells, which increases microvascular protein and fluid leakage into the interstitium ([@b18-etm-0-0-4626]).

It has been suggested that there is a link between oxidative stress and levels of inflammatory cytokines. For example, the potent pro-inflammatory cytokine interleukin (IL)-1β may trigger nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, which can produce free radical including superoxide anions. In turn, superoxide anion-induced nuclear factor-κB (NF-κB) serves an important in the production of cytokines ([@b19-etm-0-0-4626]). In this context, antioxidants from natural sources may provide novel possibilities for inhibiting UVB-induced oxidative stress-mediated events ([@b4-etm-0-0-4626]).

Pomegranates contain fibre, pectin, sugar and several tannins ([@b20-etm-0-0-4626]), as well as flavonoids and anthocyanidins in their seed oil and juice ([@b21-etm-0-0-4626]). Kim *et al* ([@b22-etm-0-0-4626]) demonstrated that pomegranates possess chemopreventative and adjuvant therapeutic effects against human breast cancer cells. Due to such biological activities, the consumption of pomegranate-containing foods is increasing ([@b21-etm-0-0-4626]).

In a previous study by our group, it was determined that pomegranate juice concentrated solution (PCS) exhibited protective effects against UVB-induced photoaging in *in vivo* and *in vitro* model systems ([@b23-etm-0-0-4626],[@b24-etm-0-0-4626]). Additionally, dried pomegranate juice concentrated powder (PCP) significantly inhibited melanin formation in B16F10 melanocytes ([@b25-etm-0-0-4626]). Thus, it is hypothesized that PCP may exert protective effects against photoaging.

The aim of the present study was to examine the anti-aging effect of PCP in UVB-induced skin photoaging. An oral dose of 2 ml/kg PCS was used as a reference, as it has been demonstrated that PCS exerts protective effects against UVB-induced skin photoaging ([@b23-etm-0-0-4626],[@b24-etm-0-0-4626]).

Materials and methods
=====================

### Animals and husbandry

A total of 66 6-week healthy female SKH-1 hairless mice were obtained from Orient Bio, Inc. (Seongnam, Korea). The experimental groups were divided into the following 6 groups (8 mice per group), based on the body weights 7 days after accclimatization (23.32±0.93 g, range, 21.4--24.8 g/head): Intact vehicle control-unexposed (mice received vehicle-control); UVB control-UVB exposed (mice received vehicle control and UVB exposure); PCS-UVB exposed (mice received PCS 2 ml/kg and UVB exposure); PCP 100 mg/kg-UVB exposed (mice received PCP 100 mg/kg and UVB exposure); PCP 200 mg/kg-UVB exposed (mice received PCP 200 mg/kg and UVB exposure); and PCP 400 mg/kg-UVB exposed (mice received PCP 400 mg/kg and UVB exposure). During acclimatization and experimental periods, animals were kept at a temperature of 20--25°C, a humidity of 50--55% and were exposed to a 12-h light/dark cycle in polycarbonate cages (4 rats per cage). Mice had *ad libitum* access to standard rodent chow (Samyang Corporation, Seoul, Korea) and tap water. All procedures involving laboratory animals followed the national regulations for the usage and welfare of laboratory animals ([@b26-etm-0-0-4626]). The protocol of the current study was approved by the Institutional Animal Care and Use Committee of Daegu Haany University (Gyeongsan, Korea) prior to the experiment (approval no. DHU2015-066).

### UVB irradiation

UVB irradiation was performed three times a week for 15 weeks at 0.18 J/cm^2^ following the protocol of a previous study ([@b27-etm-0-0-4626]). Peak emission was measured at 312 nm using a UV Crosslinker system (Hoefer Scientific Instruments, San Francisco, CA, USA). Unexposed intact control mice were also exposed to the non-emitting Crosslinker system for the same duration as the UVB-exposed hairless mice.

### Preparation and administration of test materials

PCS was purchased from ASYA Meyve Suyu ve Gida San. A.Ş. (Ankara, Turkey). PCS contained 2.31 mg/g ellagic acid as an active ingredient and consisted of 58.86% carbohydrate, 1.21% total protein, 0.49% fat, 27.97% water, 1.47% ash and 10% unidentified ingredients, as well as 28.03 mg/100 g sodium at proximate analysis. Health-Love Co. (Anyang, Korea) purchased raw materials of PCS and PCP from ASYA Meyve Suyu ve Gida San. A.Ş. and supplied the processed products after ingredients analysis and quality control. PCP (ASYA Meyve Suyu ve Gida San. A.Ş.) containing 1.15 mg/g ellagic acid and 0.22 mg/g punicalagin as active ingredients. All test materials were stored at 4°C in a refrigerator to protect from light and moisture. A PCP dose of 200 mg/kg was selected based on the *in vitro* skin whitening effect ([@b25-etm-0-0-4626]) and the clinical dose in humans \[mouse dosage was 200 mg/kg, \~12-fold the human dosage; (1,000 mg/60 kg) ×12=200 mg/kg\] and doses of 400 and 100 mg/kg were selected as the highest and lowest doses, respectively, using a ratio of 2. Similarly, a PCS dose of 2 ml/kg was selected based on a previous efficacy study investigating UVB-induced photoaging ([@b23-etm-0-0-4626],[@b24-etm-0-0-4626]) and also based on the clinical dose in humans \[mouse dosage was \~12-fold the human dosage; (10 ml/60 kg) ×12=2 ml/kg\]. PCP was dissolved in distilled water to obtain concentrations of 40, 20 and 10 mg/ml, and a volume of 10 ml/kg was orally administered using a gastric gavage attached syringe, resulting in administration of 400, 200 and 100 mg/kg, respectively. PCS was diluted in distilled water in 1:4 ratios (v/v) and a volume of 10 ml/kg was orally administered, resulting in administration of 2 ml/kg of body weight, respectively. The different doses of PCP 100, 200 and 400 mg/kg, and PCS 2 ml/kg were administered to 8 mice in each PCP group once per day for 15 weeks beginning 1 h after initial UVB exposure. Equal volumes of vehicle (distilled water) were orally administered to all mice in the intact and UVB control groups.

### Generation of replicas and image analysis

After obtaining photos of the dorsal skin around the gluteal region, animals were sacrificed by over exdanguination through vena cava under anesthesia (3% isoflurane; Hana Pharm Co., Ltd., Hwasung, Korea) and dissected. Replicas of mouse dorsal skin were obtained using the Repliflo Cartridge kit (CuDerm Corp., Dallas, TX, USA). Impression replicas were set on a horizontal sample stand and wrinkle shadows were produced by illumination with a fixed-intensity light at a 40° angle. Black and white images were recorded using a CCD camera and analyzed using the Skin-Visiometer® VL650 (Courage and Khazaka, Cologne, Germany). To analyze skin wrinkles, the average length and average depth of wrinkles were measured using a previously described method ([@b10-etm-0-0-4626]).

### Edema evaluation

To assess the effects of PCP and PCS on UVB-induced skin edema, changes in dorsal skin weight were examined using a previously established method ([@b4-etm-0-0-4626]). Dorsal skin was removed, a 6-mm diameter was delimited with the aid of a punch and this area was then weighed. Changes were measured following 15 weeks of continuous oral administration of PCP, PCS or distilled water. The results were calculated by comparing the weight of the skin between groups and expressed as g/6-mm diameter of dorsal skin.

### Skin water content measurement

The day after the final administration of test substances, 6 mm-diameter of dorsal back skin samples were removed and skin water contents (%) were measured using an automated moisture analyzer balance (MB23; Ohaus Corporation, Parsippany, NJ, USA), according to a previous study ([@b28-etm-0-0-4626]).

### Detection of collagen type I (COL1) contents in skin tissue

COL1 contents were measured following a previously established method ([@b29-etm-0-0-4626]). Briefly, parts of the dorsal back skin tissues were separated and tissue homogenates were prepared using a homogenization system (Model TacoTMPre; GeneResearch Biotechnology Corp., Taichung, Taiwan), an ultrasonic cell disruptor (Model KS-750; Madell Technology Corp., Ontario, CA, USA) and radioimmunoprecipitation assay buffer (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany). Following the seperation of supernatants by centrifugation at 21,000 × g for 10 min at 4°C, the amount of pro-collagen type I was measured using a pro-collagen type I C peptide assay kit (Takara Bio, Inc., Otsu, Japan) according to the manufacturer\'s protocol and absorbance was measured at 450 nm using a microplate reader (Tecan Group Ltd., Männedorf, Switzerland).

### Hyaluronan contents in skin tissue

Hyaluronan contents in the supernatant prepared from skin tissue homogenates were measured using a previously described method ([@b30-etm-0-0-4626]). Briefly, the fat in the sampled dorsal back skins was removed using acetone. Samples were then dried, weighed and boiled for 20 min in 50 mM Tris/HCl (pH 7.8) buffer. Subsequently, samples underwent proteolytic digestion with 1% w/v actinase E (Sigma-Aldrich; Merck KGaA) for 1 week at 40°C. Trichloroacetic acid (Sigma-Aldrich; Merck KGaA) was added to the samples at a final concentration of 10% w/v to induce deproteinization prior to centrifugation at 4,000 × g at 4°C for 20 min. The supernatants were subsequently neutralized using 10 N NaOH. Hyaluronan levels were measured using the QnE hyaluronic acid enzyme-linked immunosorbent assay (ELISA) kit (cat no. BTP-96200; Biotech Trading Partners, Encinitas, CA, USA), according to the manufacturer\'s protocol. Color intensity was measured at 450 nm using a spectrophotometer (OPTIZEN POP, Mecasys, Daejeon, Korea).

### Measurement of myeloperoxidase (MPO) activity

MPO activity was measured using the MPO kinetic-colorimetric assay, according to a previously described method ([@b4-etm-0-0-4626]). A total of 50 mM K~2~HPO~4~ buffer (pH 6.0; Sigma-Aldrich; Merck KGaA) containing 0.5% hexadecyltrimethylammonium bromide (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) was used to collect and homogenize skin samples in an ice bath for 15 sec. Following centrifugation at 1,000 × g for 2 min at 4°C, the supernatant was removed. A total of 30 µl supernatant sample was mixed with 200 µl 0.05 M K~2~HPO~4~ buffer (pH 6.0), containing 0.167 mg/ml o-dianisidine dihydrochloride (Sigma-Aldrich; Merck KGaA) and 0.05% hydrogen peroxide. After 5 min, the absorbance of the samples was measured using a spectrophotometer at 450 nm. The MPO activity of samples was compared with a standard curve of neutrophils and protein levels in the skin homogenates was measured using the Lowry method ([@b31-etm-0-0-4626]). The results are presented as MPO activity (number of total neutrophils/mg protein).

### Detection of IL-1β and IL-10 in skin tissue

The dorsal back skin tissue from the area around gluteal region was collected. Collected tissue was homogenized and processed as described by Botelho *et al* ([@b32-etm-0-0-4626]). IL-10 and IL-1β concentrations were determined using the enzyme-linked immunosorbent assay (ELISA) kit (cat no. ab108870 for IL-10; cat no. ab100705 for IL-1β; Abcam, Cambridge, UK), according to the manufacturer\'s instructions. Absorbance was measured at 490 nm using a microplate reader.

### GSH assay

Following skin homogenization (1:3, w/w dilution) in 100 mM NaH~2~PO~4~ (pH 8.0; Sigma-Aldrich; Merck KGaA) containing 5 mM EDTA, 30% trichloroacetic acid (Sigma-Aldrich; Merck KGaA) was added to homogenates. Mixtures were then centrifuged twice (once at 1,940 × g for 6 min at 4°C and once at 485 × g for 10 min at 4°C) and the fluorescence of the resulting supernatant was measured using a fluorescence spectrophotometer (RF-5301PC; Shimadzu Corporation, Tokyo, Japan). Supernatant (100 µl) was mixed with 1 ml buffer 1 and 100 µl o-phthalaldehyde (1 mg/ml in methanol; Sigma-Aldrich; Merck KGaA). After 15 min, the absorbance was measured at 420 nm. A standard curve containing 0.0--75.0 µM GSH was prepared. Protein levels in the skin homogenates were measured using the Lowry method ([@b31-etm-0-0-4626]) and results are presented as µM GSH/mg protein. GSH levels were measured as reported previously ([@b4-etm-0-0-4626]).

### Lipid peroxidation

Protein content of the homogenate (10 mg/ml in 1.15% KCl) was measured using the Lowry method ([@b31-etm-0-0-4626]). To determine lipid peroxidation, levels of thiobarbituric acid reactive substances were measured following a previously described method ([@b33-etm-0-0-4626]). Briefly, 10% trichloroacetic acid (Sigma-Aldrich; Merck KgaA) was mixed with the homogenate and this mixture was then centrifuged at 1,000 × g at 4°C for 3 min to obtain protein-free samples. Thiobarbituric acid (0.67%) was treated and the mixture was left to stand at 100°C for 15 min. Levels of malondialdehyde (MDA), an intermediate product of lipoperoxidation, were measured by determining the difference between the absorbance at 535 and 572 nm using a microplate spectrophotometer reader. The results were reported as nM/mg of protein ([@b34-etm-0-0-4626]).

### Superoxide anion production

A nitroblue tetrazolium (NBT) assay was used to determine the production of superoxide anion in dorsal back skin tissue homogenates (10 mg/ml in 1.15% KCl), following a previously described protocol ([@b35-etm-0-0-4626]). Briefly, NBT (1 mg/ml; Sigma-Aldrich; Merck KGaA) was added to 50 µl homogenate at 37°C for 1 h. The supernatant was then removed and reduced formazan was solubilized following addition of 120 µl 2 M KOH and 140 µl dimethyl sulfoxide. NBT reduction was measured at 600 nm using a microplate spectrophotometer reader and data were normalized to the protein content.

### Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

Total RNA in the individual dorsal back skins, sampled by skin puncher 24 h following the final administration of PCP or PCS, was extracted using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to a previously described method ([@b30-etm-0-0-4626]). RNA concentration and quality was determined using a CFX96™ Real-Time system using iTaq™ SYBR-Green (both from Bio-Rad Laboratories, Inc., Hercules, CA, USA). To remove contaminating DNA, samples were treated with recombinant DNase I (DNA-free DNA Removal kit; Ambion; Thermo Fisher Scientific, Inc.). RNA was reverse-transcribed using the High-Capacity cDNA Reverse Transcription kit (Applied Biosystems; Thermo Fisher Scientific, Inc.) following the manufacturer\'s instructions. The PCR cycling conditions were as follows: Initial pre-denaturation of 95°C for 1 min, denaturation for 15 sec, annealing of 55--65°C for 20 sec and extension of 72°C for 30 sec. A total of 50 cycles were performed. The β-actin mRNA level was used as a control for tissue integrity in all samples. Primer sequences for Has 1, 2 and 3, COL1A1 and 2, MMP-1, 9 and 13, Nox2, GSH reductase and β-actin are presented in [Table I](#tI-etm-0-0-4626){ref-type="table"}. For quantitative analysis, the intact control skin tissue was used as the control, and the relative expression of Has 1, 2 and 3, COL1A1 and 2, MMP-1, 9 and 13, Nox2, GSH reductase was calculated using the 2^−ΔΔCq^ method ([@b36-etm-0-0-4626]).

### Histopathology

Samples from dorsal back skins were separated, fixed in 10% neutral buffered formalin at room temperature for 24 h, embedded in paraffin wax, cut into sections 3--4 µm thick and stained with hematoxylin and eosin (H&E) for general histopathology or Masson\'s trichrome (MT) to detect collagen fiber, according to previously established methods ([@b37-etm-0-0-4626]). The histopathological profiles of each sample were observed under a light microscope (Model 80i; Nikon Corporation, Tokyo, Japan). To quantify changes in further detail, the number of microfolds formed on the surface of epithelium (folds/mm epithelium), mean epithelial thickness (µm/epithelium) and mean numbers of inflammatory cells infiltrated in the dermis (cells/mm^2^ of dermis) were determined in general histomorphometrical analysis using image analysis software (iSolution FL ver 9.1; IMT i-solution Inc., Vancouver, Canada) under H&E staining and in collagen fiber-occupied regions of the dermis (%/mm^2^ of dermis) under MT staining. The histopathologist was blinded to the group distribution when conducting the analysis.

### Immunohistochemistry

Following dewaxing of the prepared skin histological paraffin wax sections, citrate buffer antigen (epitope) retrieval pretreatment was conducted ([@b37-etm-0-0-4626]). Briefly, a water bath was pre-heated to 95--100°C with a staining dish containing 10 mM citrate buffer (pH 6.0). Slides were immersed in the staining dish for 20 min and the lid was placed loosely. The staining dish was then kept at room temperature for 20 min to cool. Sections were immunostained using avidin-biotin complex (ABC) methods for caspase-3, cleaved poly(ADP-ribose) polymerase (PARP), nitrotyrosine (NT), 4-hydroxynonenal (4-HNE), inducible nitrogen oxide synthase (iNOS) and matrix metalloproteinase (MMP)-9 according to the results of a previous study ([@b37-etm-0-0-4626]). Briefly, endogenous peroxidase activity was blocked by incubation in methanol and 0.3% H~2~O~2~ at room temperature for 30 min and non-specific binding was blocked with 1% normal horse serum blocking solution (dilution, 1:100; Vector Laboratories, Peterborough, UK) for 1 h in a humidity chamber. Sections were incubated with primary antibodies (listed in [Table II](#tII-etm-0-0-4626){ref-type="table"}) overnight at 4°C in a humidity chamber and then incubated with biotinylated universal secondary antibody (dilution, 1:50; Vector Laboratories) using a Vectastain Elite ABC kit (dilution, 1:50; Vector Laboratories; [Table II](#tII-etm-0-0-4626){ref-type="table"}) for 1 h at room temperature in a humidity chamber acooriding to the manufacturer\'s instructions. Finally, sections were incubated with a peroxidase substrate kit (Vector Laboratories; [Table II](#tII-etm-0-0-4626){ref-type="table"}) for 3 min at room temperature according to the manufacturer\'s instructions. Between steps, all sections were rinsed in 0.01 M PBS. Cells or fibers comprising \>30% immunoreactivity for each antiserum compared with intact dermal keratinocytes or dermal tissue, were regarded as positive. The mean numbers of caspase-3, PARP, NT and 4-HNE-immunoreactive epithelial cells (%, cells/100 epithelial cells) were counted using an established automated image analysis process ([@b37-etm-0-0-4626]). Additionally, the percentage of the dermis occupied by MMP-9 immunoreactive fibers was calculated (%/mm^2^ dermis). The histopathologist was blinded to the group distribution when performing the analysis.

### Statistical analyses

All data are presented as the mean ± standard deviation of eight hairless mice. Multiple comparison tests of the different groups were conducted. Variance homogeneity was examined using the Levene test and if no significant deviation from variance homogeneity was detected, the data were analyzed by a one-way analysis of variance followed by a Least Significant Difference multi-comparison test to determine whether differences between pairs of groups were significant. If significant deviations from variance homogeneity were detected by the Levene test, the non-parametric Kruskal-Wallis H comparison test was conducted. When a significant difference was observed in the Kruskal-Wallis H test, the Mann-Whitney U test with Bonferroni correction was used to determine whether there were significant differences between specific pairs of groups. Statistical analyses were performed using SPSS software ver. 14.0 for Windows (SPSS, Inc., Chicago, IL, USA) and P\<0.05 was considered to indicate a significant difference.

Results
=======

### PCP decreases wrinkle formation in UVB-exposed mice

To confirm the wrinkle alleviation effect of PCP, the mean length and depth of the wrinkles were measured ([Fig. 1](#f1-etm-0-0-4626){ref-type="fig"}). It was determined that the mean length and depth of the wrinkles were significantly greater in the skin of the UVB-exposed control mice compared with the intact control (both P\<0.01; [Fig. 2](#f2-etm-0-0-4626){ref-type="fig"}). However, these increases in wrinkle formations significantly decreased following oral administration of PCP compared with the UVB control (all P\<0.05). These decreases occurred in a dose-dependent manner ([Fig. 2](#f2-etm-0-0-4626){ref-type="fig"}).

### PCP decreases UVB-induced skin edema in UVB-exposed mice

The effect of PCP against UVB-induced skin edema was analyzed by measuring 6-mm-diameter skin weights (edema score). The 6-mm-diameter skin weights (edema score) in mice exposed to UVB were significantly greater than those of intact controls (P\<0.01). However, in mice treated with 400, 200 and 100 mg/kg PCP, mean skin weight significantly decreased (P\<0.01) compared with those of the UVB-exposed mice, by −55.33, −45.68 and −37.61%, respectively ([Fig. 3](#f3-etm-0-0-4626){ref-type="fig"}).

### PCP increases skin water content in UVB-exposed mice

To clarify the moisturizing effects of PCP, the skin water content in 6-mm-diameter tissues was observed. Skin-water content was significantly decreased following UVB treatment (P\<0.01). However, UVB-induced decreases in skin water contents were significantly reversed (P\<0.01) following treatment with 100, 200 and 400 mg/kg PCP, in a dose-dependent manner. Additionally, mice administered 2 ml/kg PCS exhibited significant increases in skin water content compared with UVB control mice (P\<0.01; [Table III](#tIII-etm-0-0-4626){ref-type="table"}).

### PCP inhibits the decreases in skin COL1 and hyaluronan content in UVB-exposed mice

To confirm the moisturizing effects of PCP, changes in COL1 and hyaluronan contents were assessed. COL1 and hyaluronan contents were significantly lower in 6-mm-diameter skin tissues from UVB control mice compared with intact controls (P\<0.01). However, these decreases were significantly inhibited following oral administration of all three doses of PCP (P\<0.01; [Table III](#tIII-etm-0-0-4626){ref-type="table"}).

### PCP decreases MPO activity and IL-1β levels while increasing IL-10 levels in UVB-exposed mice

To clarify the anti-inflammatory effects of PCP, MPO activity, as well as IL-1β and IL-10 levels, were assessed. Skin MPO activity and IL-1β levels were significantly higher in UVB-exposed control mice than intact control mice (P\<0.01). MPO activity and IL-1β levels were significantly inhibited following oral administration of PCS (P\<0.01) and all doses of PCP (P\<0.01) in a dose-dependent manner, compared with the UVB control mice ([Table IV](#tIV-etm-0-0-4626){ref-type="table"}). IL-10 levels in UVB-exposed control mice were significantly decreased compared with those in unexposed intact control mice (P\<0.01). However, significant (P\<0.05) and dose-dependent increases in skin IL-10 levels were observed following administration of all three doses of PCP compared with untreated UVB-exposed mice ([Table IV](#tIV-etm-0-0-4626){ref-type="table"}).

### PCP increases GSH content and decreases MDA levels in UVB-exposed mice

To determine the anti-oxidative effects of PCP, GSH contents and MDA levels were analyzed. GSH contents were significantly lower in the UVB-exposed mice compared with the intact control (P\<0.01; [Table V](#tV-etm-0-0-4626){ref-type="table"}). Furthermore, significant increases in skin MDA levels, indicating increased lipid peroxidation and superoxide anion production, were detected in UVB-exposed mice compared with unexposed control mice (P\<0.01; [Table V](#tV-etm-0-0-4626){ref-type="table"}).

Skin GSH contents were significantly increased in all PCP-administered hairless mice compared with UVB control mice (P\<0.01; [Table V](#tV-etm-0-0-4626){ref-type="table"}). This increase occurred in a dose-dependent manner. Furthermore, skin MDA levels and superoxide anion production were significantly decreased in PCP-treated mice compared with UVB control mice (P\<0.01; [Table V](#tV-etm-0-0-4626){ref-type="table"}).

### PCP decreases skin MMP-1, −9, and −13 and Nox2 mRNA expression in UVB-exposed mice

Although no significant changes in skin Has 1, 2, and 3 or in COL1A1 and 2 mRNA levels (relative to the control) were identified in UVB-exposed control mice compared with unexposed intact control mice, significant increases (P\<0.01) in skin Has 1, 2, and 3 and COL1A1 and 2 mRNA levels were detected in mice receiving the three doses of PCP, compared with UVB control mice, suggesting that PCP increases hyaluronan and COL1 synthesis ([Table VI](#tVI-etm-0-0-4626){ref-type="table"}).

Significant increases in skin MMP-1, −9 and −13 and Nox2 mRNA levels were detected in UVB-exposed control mice compared with unexposed intact mice (P\<0.01), indicating increased MMP activity and ROS-dependent inflammation in UVB-exposed control mice. However, levels of skin MMP and Nox2 mRNA were significantly inhibited following administration of all three doses of PCP compared with UVB control mice (P\<0.01; [Table VI](#tVI-etm-0-0-4626){ref-type="table"}).

Levels of skin GSH reductase mRNA were significantly decreased in UVB-exposed mice compared with intact control mice (P\<0.01). However, significant dose-dependent increases in skin GSH reductase mRNA expression were detected in mice receiving 100, 200 and 400 mg/kg PCP compared with UVB control mice (P\<0.01; [Table VI](#tVI-etm-0-0-4626){ref-type="table"}).

### PCP decreases histopathological dermis sclerosis and inflammatory signs in UVB-exposed mice

When the mean epithelial thicknesses of UVB-exposed mice and intact control mice were compared, it was determined that UVB-exposed control mice exhibited higher mean epithelial thicknesses of dorsal back skin tissues compared with intact control mice. In addition, there was a cellular infiltration of inflammatory cells into the epidermis, an abnormal accumulation of collagen in the dermis and the formation of microfolds on the surface of the epithelial lining was observed ([Fig. 4](#f4-etm-0-0-4626){ref-type="fig"}).

These findings were confirmed by histomorphometric analysis; significant increases in the number of epithelial surface microfolds, mean epithelial thickness, numbers of dermal infiltrating inflammatory cells and the percentages of collagen fiber-occupied dermal regions were detected in UVB-exposed mice compared with unexposed intact vehicle controls (P\<0.01). However, significant dose-dependent decreases in UVB-induced histopathological dermis sclerosis and inflammatory signs were observed in mice orally administered 100, 200 and 400 mg/kg PCP compared with UVB control mice (P\<0.01). At an oral dose of 2 ml/kg, PCS was also associated with significant decreases in epithelial surface microfolds, mean epithelial thickness, numbers of dermal infiltrating inflammatory cells and percentages of collagen fiber-occupied dermal regions compared with the UVB control (P\<0.05; [Table VII](#tVII-etm-0-0-4626){ref-type="table"}).

### PCP decreases NT-4-HNE-, caspase-3- and PARP-positive cells and decreases dermal MMP-9-immunoreactivity cells in UVB-exposed mice

Notable increases in the number of cells immunolabeled for oxidative stress (NT and 4-HNE) and apoptosis (caspase-3 and PARP) markers were detected among epidermal keratinocytes on the dorsal back skin tissues in UVB-exposed control mice, with marked increases in dermal MMP-9 immunoreactivity ([Fig. 5](#f5-etm-0-0-4626){ref-type="fig"}). These changes were confirmed by histomorphometric analyses; significant increases in epithelial NT-, 4-HNE-, caspase-3- and PARP-immunoreactive cells as well as dermal MMP-9 immunoreactivity, were observed in UVB-exposed control mice compared with unexposed control mice (P\<0.01; [Table VIII](#tVIII-etm-0-0-4626){ref-type="table"}). However, significant decreases in oxidative stress and apoptosis markers and dermal MMP-9 immunoreactivity were observed in mice treated with 2 ml/kg PCS and 100, 200 and 400 mg/kg PCP compared with UVB-exposed mice (P\<0.01; [Table VII](#tVII-etm-0-0-4626){ref-type="table"}). In particular, PCP induced clear dose-dependent decreases in epithelial NT-, 4-HNE-, caspase-3- and PARP-positive cells, as well as dermal MMP-9-immunoreactive cells ([Table VIII](#tVIII-etm-0-0-4626){ref-type="table"} and [Fig. 5](#f5-etm-0-0-4626){ref-type="fig"}).

Discussion
==========

Prolonged human exposure to sunlight results in unwanted and deleterious effects, including the development of cancer, wrinkles, scales, dryness and mottled pigment abnormalities (hyper- or hypopigmentation) ([@b4-etm-0-0-4626]--[@b6-etm-0-0-4626]). Furthermore, acute exposure to UV radiation may stimulate the migration of inflammatory cells, such as neutrophils ([@b38-etm-0-0-4626]). Inflammation may cause skin damage, premature skin aging and skin cancer ([@b39-etm-0-0-4626]). Additionally, chronic photoaging triggers marked hyperplasia of epidermal cells with hyperkeratosis, leading to wrinkle formation ([@b40-etm-0-0-4626]). The results of the current study demonstrated that PCP (100, 200 and 400 mg/kg) significantly inhibits UVB-induced wrinkle formation and hyperplasia/hypertrophy of the epithelial keratocytes. Pomegranate extracts contain anthocyanins, ellagitannins and hydrolyzable tannins, and oral administration of these extracts reduces UVB-induced carcinogenesis in mice ([@b41-etm-0-0-4626],[@b42-etm-0-0-4626]). Ellagic acids contained in pomegranates exhibit antimutant, antiviral, antioxidant and skin-whitening activity and are already used in Japan as a food additive ([@b43-etm-0-0-4626]). It has also been suggested that punic acid in pomegranate seed oil may prevent 7,12-dimethylbenz(a)anthracene (DMBA)- and 12-*O*-tetradecanoylphorbol-13-acetate (TPA)-induced skin cancer ([@b44-etm-0-0-4626],[@b45-etm-0-0-4626]).

Increased vascular permeability and blood flow are induced by inflammatory chemical mediators, including the cyclooxygenase-derived metabolites of arachidonic acid ([@b46-etm-0-0-4626]). UVB light-induced edema in hairless mice and erythema in humans can be explained by the same mechanism ([@b4-etm-0-0-4626],[@b6-etm-0-0-4626]). In the current study, the administration of PCP was able to inhibit skin edema in animals exposed to UVB irradiation.

Generally, UVB irradiation stimulates the production of ROS, such as superoxide anions, are important factors ([@b46-etm-0-0-4626]) in the process of neutrophil recruitment to inflammatory foci. Neutrophils are the first cells to be recruited from the peripheral blood to inflammatory sites ([@b4-etm-0-0-4626],[@b47-etm-0-0-4626]). Inflammatory cells serve an important role in eliminating the causes of inflammation ([@b48-etm-0-0-4626]), whereas activated polymorphonuclear leukocytes (PMNs) are a potential source of oxygen metabolites and may exacerbate inflammation ([@b49-etm-0-0-4626]). UVB irradiation increases the activity of MPO, an activating cytotoxic enzyme released from PMNs ([@b4-etm-0-0-4626],[@b14-etm-0-0-4626],[@b15-etm-0-0-4626],[@b47-etm-0-0-4626]). Thus, reduced neutrophil influx into the skin tissue may be confirmed by a reduction in MPO activity ([@b32-etm-0-0-4626]). Nox enzymes are involved in the generation of endogenous ROS in response to inflammatory mediators, including cytokines, growth factors and hypoxic conditions ([@b50-etm-0-0-4626],[@b51-etm-0-0-4626]). Nox2 is predominantly expressed in myeloid white blood cells ([@b52-etm-0-0-4626]). The results of the current study indicated that PCP decreased UVB-induced MPO activity and dermis inflammatory cell infiltration. Additionally, all three doses of PCP and PCS inhibited the expression of Nox2 mRNA and the production of superoxide anions ([@b46-etm-0-0-4626],[@b53-etm-0-0-4626]). These results support the hypothesis that the antioxidant effect of PCP inhibits the inflammatory processes induced by UVB irradiation.

Following exposure to UVB, human keratinocytes exhibit increased expression of cytokines, including TNF-α, IL-1α, IL-1β and IL-6 ([@b4-etm-0-0-4626],[@b6-etm-0-0-4626],[@b17-etm-0-0-4626]). IL-1β-stimulated neutrophils and other cells upregulate the expression of intercellular adhesion molecules ([@b54-etm-0-0-4626]). UVB-induced inflammasomes serve an important in regulating the activation of IL-1β. Activation of nucleotide-binding oligomerization domain-containing protein (NOD) 1 and NOD2 by UVB leads to the recruitment of the adapter apoptosis-associated speck-like protein, resulting in the activation of pro-caspase-1 into its cleaved form ([@b55-etm-0-0-4626]). Consequently, caspase-1-depedent cleavage stimulates the activation of IL-1β by pro-IL-1β ([@b56-etm-0-0-4626]). The results of the current study indicated that IL-1β levels in the PCP- and PCS-treated groups were lower than those in the UVB-exposed group. The inhibition of IL-1β production by PCP is consistent with the inhibition of MPO activity, as IL-1β is chemotactic for neutrophils ([@b57-etm-0-0-4626]). Inhibition of IL-1β production by PCP may lead to a reduction in neutrophil recruitment and consequently, to a reduction in MPO activity. Furthermore, PCP inhibited *gp91phox* mRNA expression and the production of superoxide anions; these findings suggest that preventing ROS-mediated IL-1β production may be a mechanism of action of PCP against the effects of UVB irradiation.

IL-10 is a potent anti-inflammatory cytokine that blocks NF-κB activity. It regulates inflammatory signaling by reducing levels of UVB radiation-induced pro-inflammatory cytokines ([@b54-etm-0-0-4626]). Decreases in the levels of UVB-induced IL-10 in the present study were consistent with the results reported by Campanini *et al* ([@b4-etm-0-0-4626]). These decreases were reversed following treatment with PCP; thus the protective mechanism of PCP against UVB may be associated with an increase in IL-10 production.

GSH is a sensitive marker of oxidative stress caused by UVB irradiation ([@b58-etm-0-0-4626]). 4-HNE is a tissue lipid peroxidation marker and is regarded as a potential causal agent in many diseases including chronic inflammation, neurodegenerative disease, adult respiratory distress syndrome, atherogenesis, diabetes and certain types of cancer ([@b59-etm-0-0-4626]). NT has been identified in the process of tyrosine nitration that is mediated by reactive nitrogen species, including the peroxynitrite anion and nitrogen dioxide, and can be generated by the myeloperoxidase system ([@b60-etm-0-0-4626]). NT is considered to be an iNOS-dependent marker ([@b61-etm-0-0-4626]). The results of the current study indicated that PCP inhibits the depletion of endogenous antioxidants. These results suggest that PCP exerts antioxidant activity by maintaining the GSH system and defending against the oxidative stress associated with exposure to UVB.

Previous studies have demonstrated that, in hairless mice, prolonged exposure to UVB causes significant increases in the levels of MMP-1, −9, and −13 ([@b62-etm-0-0-4626],[@b63-etm-0-0-4626]). MMPs are directly responsible for the skin photoaging process; thus, the direct inhibition of MMP activity with a specific inhibitor or the indirect inhibition of MMP by reduction of its expression may be an effective therapeutic method of counteracting photoaging ([@b9-etm-0-0-4626],[@b37-etm-0-0-4626]). In the present study, UVB treatment increased MMP activity and associated abnormal dermal collagen deposition was significantly inhibited following treatment with PCP and PCS. These results indicate that PCP may be effective at preventing photoaging by reducing the expression of MMPs.

UV-mediated mass apoptosis may damage the normal barrier function of the skin and exacerbate skin photoaging ([@b64-etm-0-0-4626]). It has been demonstrated that UVB-induced apoptosis enhances the expression of caspase-3 and PARP-immunoreactive keratinocytes in the skin epithelium ([@b7-etm-0-0-4626],[@b64-etm-0-0-4626]). The results of the present study determined that increases in epidermal apoptotic markers were dose-dependently inhibited by oral administration of the three doses of PCP and PCS. These observations suggest that PCP may be effective against photoaging by inhibiting epidermal keratinocyte apoptosis ([@b7-etm-0-0-4626],[@b64-etm-0-0-4626]).

Normal human keratin layers contain 10--20% water, however loss of water content increases wrinkle formation and itching ([@b50-etm-0-0-4626]). The COL1A1 and COL1A2 genes encode the component COL1, part of the major structural protein type I procollagen ([@b65-etm-0-0-4626]). Collagen destruction is thought to be responsible for the appearance of aged skin and changes resulting from chronic sun exposure ([@b66-etm-0-0-4626]). It has been suggested that skin wrinkles and ECM degradation are associated with an increase in the activities of dermal enzymes, including hyaluronidase, collagenase, elastase and MMP-1 ([@b67-etm-0-0-4626]). Hyaluronan, a major ECM component, serves an important role in maintaining water homeostasis in the skin ([@b23-etm-0-0-4626],[@b30-etm-0-0-4626]) and the synthesis of Has 1, 2, and 3 ([@b30-etm-0-0-4626]). According to the results of the current study, the groups receiving PCP exhibited increased skin water, COL1 and hyaluronan content. Furthermore, the groups exhibited upregulation of COL1A1 and 2, and of Has 1, 2, and 3 mRNA expression. In particular, levels of COL1A1 and 2, and Has 1, 2, and 3 in mice receiving 100 mg/kg PCP increased more than those in mice receiving 2 ml/kg PCS.

There were a few limitations of the present study. SKH-1 hairless mice are wildly used to examine the mechanism and protection of age-related skin changes ([@b40-etm-0-0-4626]) however, UV-developed wrinkles differ from those in humans as they arise following chronic ultraviolet radiation (UVR) exposure and are associated with epidermal rather than dermal changes ([@b68-etm-0-0-4626],[@b69-etm-0-0-4626]). The UVR-exposed dermis in SKH1 mice exhibits elastic fiber hyperplasia, collagen degradation and elevated glycosaminoglycans, which are associated with alterations in the activity of MMPs. UVR-developed wrinkles in SKH1 mice occur as prominent horizontal creases on the dorsum. In addition, experimental results from the mice model cannot directly be applied to humans due to differences between evaluations of animal target studies and clinically usable evaluations.

Taken together, the results of the current study indicate that protection against UVB-induced photoaging was achieved by treatment with different doses of PCP (100, 200 and 400 mg/kg) and 2 ml/kg PCS. This was due to the active cytoprotective and anti-apoptotic effects, MMP activity inhibition and ECM (COL1 and hyaluronan) synthesis-related moisturizing, anti-inflammatory and anti-oxidative effects of PCP and PCS. PCP may therefore be developed as a functional protective agent against UVB-induced skin photoaging. According to the results of the current study, skin aging induced by UVB is most effectively suppressed by treatment with 200 mg/kg PCP. In humans, the equivalent dose is 1 g/person for humans. Therefore, the clinical efficacy of 1 g/person PCP against skin photoaging in humans should be investigated further.

The present study was supported by the National Research Foundation of Korea grant funded by the Korean government (grant no. 2012R1A5A2A42671316). The authors Mr Beom-Rak Choi, Mrs Seung-Hee Kim, Mrs Hae-Yeon Yi and Mrs Hye-Rim Park are employees at Health-Love Co., Ltd.
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![Representative gross images of dorsal back skin (top panel) and replicas (bottom panel) taken from unexposed intact or UVB-exposed hairless mice. (A) Unexposed normal vehicle control hairless mice treated with distilled water; (B) UVB-exposed vehicle control hairless mice administered distilled water; (C) UVB-exposed hairless mice administered 2 ml/kg PCS; (D) UVB-exposed hairless mice administered 100 mg/kg PCP; (E) UVB-exposed hairless mice administered 200 mg/kg PCP; (F) UVB-exposed hairless mice administered 400 mg/kg PCP. Scale bars=10 mm; UVB, ultraviolet B; PCP, dried pomegranate juice concentrated powder; PCS, pomegranate juice concentrated solution.](etm-14-02-1023-g00){#f1-etm-0-0-4626}

![Changes in the mean length and depth of wrinkles in skin replicas following 15 weeks continuous oral administration of PCP or PCS in UVB-exposed mice. Significant increases in (A) mean length and (B) average depth of skin wrinkles were detected in the skin replicas of UVB control mice compared with the intact controls. Values are expressed as the mean ± standard deviation (n=8). P-values were determined by the least significant difference test. \*P\<0.05 and \*\*P\<0.01 vs. intact control; ^†^P\<0.01 vs. UVB control. UVB, ultraviolet B; PCP, dried pomegranate juice concentrated powder; PCS, pomegranate juice concentrated solution.](etm-14-02-1023-g01){#f2-etm-0-0-4626}

![Changes in skin edema scores. The graph presents the 6-mm diameter skin weights following 15 weeks continuous oral administration of PCP or PCS in UVB-exposed mice. Values are expressed the mean ± standard deviation (n=8). P-values were determined by the least significant difference test. \*P\<0.05 and \*\*P\<0.01 vs. intact control; ^†^P\<0.01 vs. UVB control. UVB, ultraviolet B; PCP, dried pomegranate juice concentrated powder; PCS, pomegranate juice concentrated solution.](etm-14-02-1023-g02){#f3-etm-0-0-4626}

![Representative histological images of dorsal back skin tissues taken from unexposed intact or UVB exposed hairless mice. (A) Intact vehicle control; (B) UVB control; (C) UVB-exposed mice treated with 2 ml/kg PCS; (D) UVB-exposed mice treated with 100 mg/kg PCP; (E) UVB-exposed mice treated with 200 mg/kg PCP; (F) UVB-exposed mice treated with 400 mg/kg PCP. Arrows indicate microfolds formed. Scale bars=100 µm. UVB, ultraviolet B; MT, Masson\'s trichrome; PCP, dried pomegranate juice concentrated powder; PCS, pomegranate juice concentrated solution.](etm-14-02-1023-g03){#f4-etm-0-0-4626}

![Representative immunohistochemistrical images of dorsal back skin tissues, taken from unexposed intact or UVB-exposed hairless mice. (A) Intact vehicle control; (B) UVB control; (C) UVB-exposed mice treated with 2 ml/kg PCS mice; (D) UVB-exposed mice treated with 100 mg/kg PCP; (E) UVB-exposed mice treated with 200 mg/kg PCP; (F) UVB-exposed mice treated with 400 mg/kg PCP. All avidin-biotin complex immunostaining. Scale bars=50 µm. UVB, ultraviolet B; 4-HNE, 4-hydroxynonenal; PARP, cleaved poly(ADP-ribose) polymerase; MMP-9, matrix metalloproteinase 9; PCP, dried pomegranate juice concentrated powder; PCS, pomegranate juice concentrated solution.](etm-14-02-1023-g04){#f5-etm-0-0-4626}

###### 

Primer sequences for reverse transcription-quantitative polymerase chain reaction.

  Target          Primer sequence (5′-3′)
  --------------- ------------------------------
  Has 1           
    Forward       GCATGGGCTATGCTACCAAGTAT
    Reverse       AGGAGGGCGTCTCCGAGTA
  Has 2           
    Forward       GACCCTATGGTTGGAGGTGTTG
    Reverse       ACGCTGCTGAGGAAGGAGATC
  Has 3           
    Forward       AGACCGAGCTAGCCTTCCTAGT
    Reverse       TAATGGCCAGATACAGCATGAG
  COL1A1          
    Forward       GCGGTAACGATGGTGCTGTT
    Reverse       CTTCACCCTTAGCACCAAC
  COL1A2          
    Forward       ATTGTCGCCAGTGAG
    Reverse       CTGGTCCTGCTGGT
  MMP-1           
    Forward       AAGGTTAGCTTACTGTCACACGCTT
    Reverse       CGACTCTAGAAACACAAGAGCAAGA
  MMP-9           
    Forward       CCCGGACCAAGGATACAG
    Reverse       GGCTTTCTCTCGGTACTG
  MMP-13          
    Forward       CATCCATCCCGTGACCTTAT
    Reverse       GCATGACTCTCACAATGCGA
  GSH reductase   
    Forward       TGCGTGAATGTTGGATGTGTACCC
    Reverse       CCGGCATTCTCCAGTTCCTCG
  Nox2            
    Forward       AGCTATGAGGTGGTGATGTTAGTGG
    Reverse       CACAATATTTGTACCAGACAGACTTGAG
  β-actin         
    Forward       AGCTGCGTTTTACACCCTTT
    Reverse       AAGCCATGCCAATGTTGTCT

Has, hyaluronic acid synthase; COL1A, collagen, type I α; MMP, matrix metalloproteinase; GSH reductase, glutathione reductase; Nox2, *gp91phox* subunit of the phagocyte NADPH oxidase.

###### 

Primary antiserum and detection kits used in the present study.

  Product                                                                 Catalog no.   Supplier                                           Dilution
  ----------------------------------------------------------------------- ------------- -------------------------------------------------- ----------
  Primary antiserums                                                                                                                       
    Anti-cleaved caspase-3 (Asp175) polyclonal antibody                   9661          Cell Signaling Technology Inc., Danvers, MA, USA   1:400
    Anti-cleaved poly(ADP-ribose) polymerase (Asp214) specific antibody   9545          Cell Signaling Technology Inc., Danvers, MA, USA   1:100
    Anti-4-Hydroxynonenal polyclonal antibody                             Ab46545       Abcam, Cambridge, UK                               1:100
    Anti-Nitrotyrosine polyclonal antibody                                06--284       EMD Millipore, Billerica, MA, USA                  1:200
    Anti-Matrix metalloprotease-9 mouse antibody                          Ab38898       Abcam, Cambridge, UK                               1:100
  Detection kits                                                                                                                           
    Vectastain Elite ABC kit                                              PK-6200       Vector Laboratories, Inc., Burlingame, CA, USA     1:50
    Peroxidase substrate kit                                              SK-4100       Vector Laboratories, Inc., Burlingame, CA, USA     1:50

All antiserums were diluted with 0.01 M phosphate buffered saline.

###### 

Changes in skin water, COL1 and hyaluronan contents following 15 weeks continuous oral administration of PCP or PCS in UVB-exposed mice.

  Groups          Skin water contents (%/6 mm-diameter skin)                                                              Skin COL1 contents (%)                                                                                  Skin hyaluronan contents (ng/ml)
  --------------- ------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------
  Controls                                                                                                                                                                                                                        
    Intact        37.14±3.47                                                                                              98.61±14.32                                                                                             2.51±0.54
    UVB           17.96±3.05^[a](#tfn4-etm-0-0-4626){ref-type="table-fn"}^                                                44.41±10.53^[a](#tfn4-etm-0-0-4626){ref-type="table-fn"}^                                               1.01±0.18^[a](#tfn4-etm-0-0-4626){ref-type="table-fn"}^
  Reference                                                                                                                                                                                                                       
    PCS 2 ml/kg   26.54±2.80^[a](#tfn4-etm-0-0-4626){ref-type="table-fn"},[b](#tfn5-etm-0-0-4626){ref-type="table-fn"}^   58.16±5.50^[a](#tfn4-etm-0-0-4626){ref-type="table-fn"},[b](#tfn5-etm-0-0-4626){ref-type="table-fn"}^   1.35±0.20^[a](#tfn4-etm-0-0-4626){ref-type="table-fn"},[b](#tfn5-etm-0-0-4626){ref-type="table-fn"}^
  PCP                                                                                                                                                                                                                             
    100 mg/kg     26.74±2.42^[a](#tfn4-etm-0-0-4626){ref-type="table-fn"},[b](#tfn5-etm-0-0-4626){ref-type="table-fn"}^   58.82±7.44^[a](#tfn4-etm-0-0-4626){ref-type="table-fn"},[b](#tfn5-etm-0-0-4626){ref-type="table-fn"}^   1.42±0.14^[a](#tfn4-etm-0-0-4626){ref-type="table-fn"},[b](#tfn5-etm-0-0-4626){ref-type="table-fn"}^
    200 mg/kg     29.66±3.31^[a](#tfn4-etm-0-0-4626){ref-type="table-fn"},[b](#tfn5-etm-0-0-4626){ref-type="table-fn"}^   65.34±8.57^[a](#tfn4-etm-0-0-4626){ref-type="table-fn"},[b](#tfn5-etm-0-0-4626){ref-type="table-fn"}^   1.68±0.21^[a](#tfn4-etm-0-0-4626){ref-type="table-fn"},[b](#tfn5-etm-0-0-4626){ref-type="table-fn"}^
    400 mg/kg     32.18±2.86^[a](#tfn4-etm-0-0-4626){ref-type="table-fn"},[b](#tfn5-etm-0-0-4626){ref-type="table-fn"}^   73.83±6.30^[a](#tfn4-etm-0-0-4626){ref-type="table-fn"},[b](#tfn5-etm-0-0-4626){ref-type="table-fn"}^   1.82±0.21^[a](#tfn4-etm-0-0-4626){ref-type="table-fn"},[b](#tfn5-etm-0-0-4626){ref-type="table-fn"}^

Values are expressed as mean ± standard deviation (n=8).

P\<0.01 vs. intact control

P\<0.01 vs. UVB control. UVB, ultraviolet B; PCS, pomegranate juice concentrated solution; PCP, dried pomegranate juice concentrated powder; COL1, collagen type I.

###### 

Changes in skin MPO activity, IL-1β and IL-10 levels following 15 weeks continuous oral administration of PCP or PCS in UVB-exposed mice.

  Groups          MPO (Numbers of neutrophils ×10^5^/mg protein)                                                         IL-1β (pg/100 mg protein)                                                                                 IL-10 (pg/100 mg protein)
  --------------- ------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------
  Controls                                                                                                                                                                                                                         
    Intact        1.41±0.42                                                                                              20.43±3.28                                                                                                318.88±72.13
    UVB           11.14±2.38^[a](#tfn7-etm-0-0-4626){ref-type="table-fn"}^                                               62.10±11.63^[a](#tfn7-etm-0-0-4626){ref-type="table-fn"}^                                                 146.63±30.91^[a](#tfn7-etm-0-0-4626){ref-type="table-fn"}^
  Reference                                                                                                                                                                                                                        
    PCS 2 ml/kg   7.77±1.72^[a](#tfn7-etm-0-0-4626){ref-type="table-fn"},[b](#tfn8-etm-0-0-4626){ref-type="table-fn"}^   42.63±5.49^[a](#tfn7-etm-0-0-4626){ref-type="table-fn"},[b](#tfn8-etm-0-0-4626){ref-type="table-fn"}^     192.63±8.85^[a](#tfn7-etm-0-0-4626){ref-type="table-fn"},[b](#tfn8-etm-0-0-4626){ref-type="table-fn"}^
  PCP                                                                                                                                                                                                                              
    100 mg/kg     7.38±1.60^[a](#tfn7-etm-0-0-4626){ref-type="table-fn"},[b](#tfn8-etm-0-0-4626){ref-type="table-fn"}^   41.53±11.02^[a](#tfn7-etm-0-0-4626){ref-type="table-fn"},[b](#tfn8-etm-0-0-4626){ref-type="table-fn"}^    211.00±44.98^[a](#tfn7-etm-0-0-4626){ref-type="table-fn"},[c](#tfn9-etm-0-0-4626){ref-type="table-fn"}^
    200 mg/kg     4.84±1.40^[a](#tfn7-etm-0-0-4626){ref-type="table-fn"},[b](#tfn8-etm-0-0-4626){ref-type="table-fn"}^   37.31±12.16^[a](#tfn7-etm-0-0-4626){ref-type="table-fn"},[b](#tfn8-etm-0-0-4626){ref-type="table-fn"}^    229.63±33.41^[a](#tfn7-etm-0-0-4626){ref-type="table-fn"},[d](#tfn10-etm-0-0-4626){ref-type="table-fn"}^
    400 mg/kg     4.41±1.19^[a](#tfn7-etm-0-0-4626){ref-type="table-fn"},[b](#tfn8-etm-0-0-4626){ref-type="table-fn"}^   31.21±10.85^[a](#tfn7-etm-0-0-4626){ref-type="table-fn"},[d](#tfn10-etm-0-0-4626){ref-type="table-fn"}^   238.00±24.37^[a](#tfn7-etm-0-0-4626){ref-type="table-fn"},[d](#tfn10-etm-0-0-4626){ref-type="table-fn"}^

Values are expressed as mean ± standard deviation (n=8).

P\<0.01 vs. intact control

P\<0.01 vs. UVB control

P\<0.05 vs. UVB control

P\<0.05 vs. intact control. IL, interleukin; MPO, myeloperoxidase; UVB, ultraviolet B; PCP, dried pomegranate juice concentrated powder; PCS, pomegranate juice concentrated solution.

###### 

Changes in the skin antioxidant defense systems following 15 weeks continuous oral administration of PCP or PCS in UVB-exposed mice.

  Groups          GSH (mg/mg protein)                                                                                      MDA (ng/mg protein)                                                                                        Superoxide anion production (OD at 600 nm)
  --------------- -------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------
  Controls                                                                                                                                                                                                                            
    Intact        0.46±0.17                                                                                                25.58±10.14                                                                                                0.36±0.12
    UVB           0.11±0.03^[a](#tfn12-etm-0-0-4626){ref-type="table-fn"}^                                                 132.59±22.30^[a](#tfn12-etm-0-0-4626){ref-type="table-fn"}^                                                1.04±0.20^[a](#tfn12-etm-0-0-4626){ref-type="table-fn"}^
  Reference                                                                                                                                                                                                                           
    PCS 2 ml/kg   0.17±0.04^[a](#tfn12-etm-0-0-4626){ref-type="table-fn"},[b](#tfn13-etm-0-0-4626){ref-type="table-fn"}^   84.49±18.89^[a](#tfn12-etm-0-0-4626){ref-type="table-fn"},[b](#tfn13-etm-0-0-4626){ref-type="table-fn"}^   0.74±0.09^[a](#tfn12-etm-0-0-4626){ref-type="table-fn"},[b](#tfn13-etm-0-0-4626){ref-type="table-fn"}^
  PCP                                                                                                                                                                                                                                 
    100 mg/kg     0.18±0.03^[b](#tfn13-etm-0-0-4626){ref-type="table-fn"},[b](#tfn13-etm-0-0-4626){ref-type="table-fn"}^   70.08±10.33^[a](#tfn12-etm-0-0-4626){ref-type="table-fn"},[b](#tfn13-etm-0-0-4626){ref-type="table-fn"}^   0.73±0.11^[a](#tfn12-etm-0-0-4626){ref-type="table-fn"},[b](#tfn13-etm-0-0-4626){ref-type="table-fn"}^
    200 mg/kg     0.24±0.03^[a](#tfn12-etm-0-0-4626){ref-type="table-fn"},[b](#tfn13-etm-0-0-4626){ref-type="table-fn"}^   59.63±8.53^[a](#tfn12-etm-0-0-4626){ref-type="table-fn"},[b](#tfn13-etm-0-0-4626){ref-type="table-fn"}^    0.63±0.17^[a](#tfn12-etm-0-0-4626){ref-type="table-fn"},[b](#tfn13-etm-0-0-4626){ref-type="table-fn"}^
    400 mg/kg     0.27±0.04^[b](#tfn13-etm-0-0-4626){ref-type="table-fn"},[c](#tfn14-etm-0-0-4626){ref-type="table-fn"}^   48.10±10.85^[a](#tfn12-etm-0-0-4626){ref-type="table-fn"},[b](#tfn13-etm-0-0-4626){ref-type="table-fn"}^   0.52±0.12^[b](#tfn13-etm-0-0-4626){ref-type="table-fn"},[c](#tfn14-etm-0-0-4626){ref-type="table-fn"}^

Values are expressed as mean ± standard deviation (n=8).

P\<0.01 vs. intact control

P\<0.01 vs. UVB control

P\<0.05 vs. intact control. MDA, malondialdehyde; GSH, glutathione; OD, optical density; UVB, ultraviolet B; PCP, dried pomegranate juice concentrated powder; PCS, pomegranate juice concentrated solution.

###### 

Changes in skin mRNA expression following 15 weeks continuous oral administration of PCP or PCS in UVB-exposed mice.

                  Control                                                                PCP                                                                                                                                                                                                                                                                                                                        
  --------------- ----------- ---------------------------------------------------------- -------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------
  Has 1           1.02±0.11   1.03±0.21                                                  1.85±0.32^[a](#tfn16-etm-0-0-4626){ref-type="table-fn"},[b](#tfn17-etm-0-0-4626){ref-type="table-fn"}^   2.41±0.37^[a](#tfn16-etm-0-0-4626){ref-type="table-fn"},[b](#tfn17-etm-0-0-4626){ref-type="table-fn"}^   2.91±0.55^[a](#tfn16-etm-0-0-4626){ref-type="table-fn"},[b](#tfn17-etm-0-0-4626){ref-type="table-fn"}^   3.89±1.17^[a](#tfn16-etm-0-0-4626){ref-type="table-fn"},[b](#tfn17-etm-0-0-4626){ref-type="table-fn"}^
  Has 2           1.05±0.11   0.99±0.11                                                  1.59±0.22^[a](#tfn16-etm-0-0-4626){ref-type="table-fn"},[b](#tfn17-etm-0-0-4626){ref-type="table-fn"}^   1.79±0.27^[a](#tfn16-etm-0-0-4626){ref-type="table-fn"},[b](#tfn17-etm-0-0-4626){ref-type="table-fn"}^   2.25±0.41^[a](#tfn16-etm-0-0-4626){ref-type="table-fn"},[b](#tfn17-etm-0-0-4626){ref-type="table-fn"}^   4.10±1.23^[a](#tfn16-etm-0-0-4626){ref-type="table-fn"},[b](#tfn17-etm-0-0-4626){ref-type="table-fn"}^
  Has 3           1.05±0.15   0.98±0.11                                                  1.58±0.41^[a](#tfn16-etm-0-0-4626){ref-type="table-fn"},[b](#tfn17-etm-0-0-4626){ref-type="table-fn"}^   1.71±0.34^[a](#tfn16-etm-0-0-4626){ref-type="table-fn"},[b](#tfn17-etm-0-0-4626){ref-type="table-fn"}^   3.05±0.93^[a](#tfn16-etm-0-0-4626){ref-type="table-fn"},[b](#tfn17-etm-0-0-4626){ref-type="table-fn"}^   3.67±1.70^[a](#tfn16-etm-0-0-4626){ref-type="table-fn"},[b](#tfn17-etm-0-0-4626){ref-type="table-fn"}^
  COL1A1          1.00±0.12   0.97±0.20                                                  2.60±0.41^[a](#tfn16-etm-0-0-4626){ref-type="table-fn"},[b](#tfn17-etm-0-0-4626){ref-type="table-fn"}^   3.03±0.56^[a](#tfn16-etm-0-0-4626){ref-type="table-fn"},[b](#tfn17-etm-0-0-4626){ref-type="table-fn"}^   3.75±0.99^[a](#tfn16-etm-0-0-4626){ref-type="table-fn"},[b](#tfn17-etm-0-0-4626){ref-type="table-fn"}^   4.76±1.62^[a](#tfn16-etm-0-0-4626){ref-type="table-fn"},[b](#tfn17-etm-0-0-4626){ref-type="table-fn"}^
  COL1A2          1.01±0.14   1.00±0.09                                                  2.62±0.45^[a](#tfn16-etm-0-0-4626){ref-type="table-fn"},[b](#tfn17-etm-0-0-4626){ref-type="table-fn"}^   3.01±0.54^[a](#tfn16-etm-0-0-4626){ref-type="table-fn"},[b](#tfn17-etm-0-0-4626){ref-type="table-fn"}^   3.74±0.98^[a](#tfn16-etm-0-0-4626){ref-type="table-fn"},[b](#tfn17-etm-0-0-4626){ref-type="table-fn"}^   4.73±1.85^[a](#tfn16-etm-0-0-4626){ref-type="table-fn"},[b](#tfn17-etm-0-0-4626){ref-type="table-fn"}^
  MMP-1           1.01±0.08   2.05±0.21^[a](#tfn16-etm-0-0-4626){ref-type="table-fn"}^   1.71±0.24^[a](#tfn16-etm-0-0-4626){ref-type="table-fn"},[b](#tfn17-etm-0-0-4626){ref-type="table-fn"}^   1.63±0.19^[a](#tfn16-etm-0-0-4626){ref-type="table-fn"},[b](#tfn17-etm-0-0-4626){ref-type="table-fn"}^   1.51±0.24^[a](#tfn16-etm-0-0-4626){ref-type="table-fn"},[b](#tfn17-etm-0-0-4626){ref-type="table-fn"}^   1.33±0.26^[a](#tfn16-etm-0-0-4626){ref-type="table-fn"},[b](#tfn17-etm-0-0-4626){ref-type="table-fn"}^
  MMP-9           1.02±0.07   1.91±0.21^[a](#tfn16-etm-0-0-4626){ref-type="table-fn"}^   1.65±0.15^[a](#tfn16-etm-0-0-4626){ref-type="table-fn"},[b](#tfn17-etm-0-0-4626){ref-type="table-fn"}^   1.55±0.18^[a](#tfn16-etm-0-0-4626){ref-type="table-fn"},[b](#tfn17-etm-0-0-4626){ref-type="table-fn"}^   1.37±0.16^[a](#tfn16-etm-0-0-4626){ref-type="table-fn"},[b](#tfn17-etm-0-0-4626){ref-type="table-fn"}^   1.24±0.11^[a](#tfn16-etm-0-0-4626){ref-type="table-fn"},[b](#tfn17-etm-0-0-4626){ref-type="table-fn"}^
  MMP-13          0.95±0.08   2.57±0.47^[a](#tfn16-etm-0-0-4626){ref-type="table-fn"}^   1.95±0.21^[a](#tfn16-etm-0-0-4626){ref-type="table-fn"},[c](#tfn18-etm-0-0-4626){ref-type="table-fn"}^   1.86±0.22^[a](#tfn16-etm-0-0-4626){ref-type="table-fn"},[b](#tfn17-etm-0-0-4626){ref-type="table-fn"}^   1.65±0.19^[a](#tfn16-etm-0-0-4626){ref-type="table-fn"},[b](#tfn17-etm-0-0-4626){ref-type="table-fn"}^   1.40±0.11^[a](#tfn16-etm-0-0-4626){ref-type="table-fn"},[b](#tfn17-etm-0-0-4626){ref-type="table-fn"}^
  GSH reductase   1.18±0.34   0.57±0.14^[a](#tfn16-etm-0-0-4626){ref-type="table-fn"}^   0.76±0.11^[a](#tfn16-etm-0-0-4626){ref-type="table-fn"},[b](#tfn17-etm-0-0-4626){ref-type="table-fn"}^   0.84±0.12^[b](#tfn17-etm-0-0-4626){ref-type="table-fn"}^                                                 1.07±0.17^[b](#tfn17-etm-0-0-4626){ref-type="table-fn"}^                                                 1.21±0.18^[b](#tfn17-etm-0-0-4626){ref-type="table-fn"}^
  Nox2            1.05±0.14   2.02±0.27^[a](#tfn16-etm-0-0-4626){ref-type="table-fn"}^   1.52±0.19^[a](#tfn16-etm-0-0-4626){ref-type="table-fn"},[b](#tfn17-etm-0-0-4626){ref-type="table-fn"}^   1.49±0.16^[a](#tfn16-etm-0-0-4626){ref-type="table-fn"},[b](#tfn17-etm-0-0-4626){ref-type="table-fn"}^   1.41±0.14^[a](#tfn16-etm-0-0-4626){ref-type="table-fn"},[b](#tfn17-etm-0-0-4626){ref-type="table-fn"}^   1.27±0.17^[b](#tfn17-etm-0-0-4626){ref-type="table-fn"},[b](#tfn19-etm-0-0-4626){ref-type="table-fn"}^

Values are expressed as mean ± standard deviation (n=8), relative expression/β-actin mRNA.

P\<0.01 vs. intact control

P\<0.01 vs. UVB control

P\<0.05 vs. UVB control

P\<0.05 vs. intact control. UVB, ultraviolet B; COL1, collagen, type I; COL1A1, COL1 α 1; COL1A2, COL1, α 2; GSH, glutathione; Has, hyaluronic acid synthase; MMP, matrix metalloproteinase; Nox2, *gp91phox* subunit of the phagocyte NADPH oxidase; PCP, dried pomegranate juice concentrated powder; PCS, pomegranate juice concentrated solution.

###### 

General histomorphometrical analysis of skin following 15 weeks continuous oral administration of PCP or PCS in UVB-exposed mice.

  Groups          No. of microfolds (folds/mm of epidermis)                                                                  Mean epithelial thickness (µm/epidermis)                                                                  Mean inflammatory cells (cells/mm^2^ of dermis)                                                             Collagen fiber occupied regions (%/mm^2^ of dermis)
  --------------- ---------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------
  Controls                                                                                                                                                                                                                                                                                                                                         
    Intact        8.75±4.40                                                                                                  19.11±2.12                                                                                                10.25±4.20                                                                                                  42.52±4.59
    UVB           70.88±14.38^[a](#tfn21-etm-0-0-4626){ref-type="table-fn"}^                                                 47.39±8.29^[a](#tfn21-etm-0-0-4626){ref-type="table-fn"}^                                                 241.25±39.15^[a](#tfn21-etm-0-0-4626){ref-type="table-fn"}^                                                 76.51±7.06^[a](#tfn21-etm-0-0-4626){ref-type="table-fn"}^
  Reference                                                                                                                                                                                                                                                                                                                                        
    PCS 2 ml/kg   46.00±11.93^[a](#tfn21-etm-0-0-4626){ref-type="table-fn"},[b](#tfn22-etm-0-0-4626){ref-type="table-fn"}^   30.60±5.51^[a](#tfn21-etm-0-0-4626){ref-type="table-fn"},[b](#tfn22-etm-0-0-4626){ref-type="table-fn"}^   186.93±24.73^[a](#tfn21-etm-0-0-4626){ref-type="table-fn"},[c](#tfn23-etm-0-0-4626){ref-type="table-fn"}^   64.92±5.26^[a](#tfn21-etm-0-0-4626){ref-type="table-fn"},[b](#tfn22-etm-0-0-4626){ref-type="table-fn"}^
  PCP                                                                                                                                                                                                                                                                                                                                              
    100 mg/kg     40.75±10.05^[a](#tfn21-etm-0-0-4626){ref-type="table-fn"},[b](#tfn22-etm-0-0-4626){ref-type="table-fn"}^   29.00±4.44^[a](#tfn21-etm-0-0-4626){ref-type="table-fn"},[b](#tfn22-etm-0-0-4626){ref-type="table-fn"}^   171.50±28.35^[a](#tfn21-etm-0-0-4626){ref-type="table-fn"},[b](#tfn22-etm-0-0-4626){ref-type="table-fn"}^   60.98±10.95^[a](#tfn21-etm-0-0-4626){ref-type="table-fn"},[b](#tfn22-etm-0-0-4626){ref-type="table-fn"}^
    200 mg/kg     33.25±10.07^[a](#tfn21-etm-0-0-4626){ref-type="table-fn"},[b](#tfn22-etm-0-0-4626){ref-type="table-fn"}^   25.72±5.61^[b](#tfn22-etm-0-0-4626){ref-type="table-fn"},[d](#tfn24-etm-0-0-4626){ref-type="table-fn"}^   149.38±32.95^[a](#tfn21-etm-0-0-4626){ref-type="table-fn"},[b](#tfn22-etm-0-0-4626){ref-type="table-fn"}^   58.64±4.25^[a](#tfn21-etm-0-0-4626){ref-type="table-fn"},[b](#tfn22-etm-0-0-4626){ref-type="table-fn"}^
    400 mg/kg     23.88±11.24^[a](#tfn21-etm-0-0-4626){ref-type="table-fn"},[b](#tfn22-etm-0-0-4626){ref-type="table-fn"}^   23.86±4.54^[b](#tfn22-etm-0-0-4626){ref-type="table-fn"}^                                                 113.88±26.82^[a](#tfn21-etm-0-0-4626){ref-type="table-fn"},[b](#tfn22-etm-0-0-4626){ref-type="table-fn"}^   54.71±4.28^[a](#tfn21-etm-0-0-4626){ref-type="table-fn"},[b](#tfn22-etm-0-0-4626){ref-type="table-fn"}^

Values are expressed as mean ± standard deviation (n=8).

P\<0.01 vs. intact control

P\<0.01 vs. UVB control

P\<0.05 vs. UVB control

P\<0.05 vs. intact control. UVB, ultraviolet B; PCP, dried pomegranate juice concentrated powder; PCS, pomegranate juice concentrated solution.

###### 

Immuno-histomorphometrical analysis of skin following 15 weeks continuous oral administration of PCP or PCS in UVB-exposed mice.

                  Epidermal immunoreactive cells (cells/100 epithelial cells)                                                                                                                                                                                                                                                                                                                                                                                 
  --------------- ---------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------
  Controls                                                                                                                                                                                                                                                                                                                                                                                                                                                    
    Intact        11.38±5.83                                                                                                 12.50±4.87                                                                                                 16.13±6.64                                                                                                 15.38±7.33                                                                                                 28.88±10.82
    UVB           82.50±11.17^[a](#tfn26-etm-0-0-4626){ref-type="table-fn"}^                                                 71.75±10.43^[a](#tfn26-etm-0-0-4626){ref-type="table-fn"}^                                                 83.00±10.20^[a](#tfn26-etm-0-0-4626){ref-type="table-fn"}^                                                 80.75±10.98^[a](#tfn26-etm-0-0-4626){ref-type="table-fn"}^                                                 75.88±13.27^[a](#tfn26-etm-0-0-4626){ref-type="table-fn"}^
  Reference                                                                                                                                                                                                                                                                                                                                                                                                                                                   
    PCS 2 ml/kg   52.00±11.12^[a](#tfn26-etm-0-0-4626){ref-type="table-fn"},[b](#tfn27-etm-0-0-4626){ref-type="table-fn"}^   53.38±11.86^[a](#tfn26-etm-0-0-4626){ref-type="table-fn"},[b](#tfn27-etm-0-0-4626){ref-type="table-fn"}^   58.25±10.95^[a](#tfn26-etm-0-0-4626){ref-type="table-fn"},[b](#tfn27-etm-0-0-4626){ref-type="table-fn"}^   52.63±11.29^[a](#tfn26-etm-0-0-4626){ref-type="table-fn"},[b](#tfn27-etm-0-0-4626){ref-type="table-fn"}^   56.63±11.48^[a](#tfn26-etm-0-0-4626){ref-type="table-fn"},[b](#tfn27-etm-0-0-4626){ref-type="table-fn"}^
  PCP                                                                                                                                                                                                                                                                                                                                                                                                                                                         
    100 mg/kg     47.50±8.99^[a](#tfn26-etm-0-0-4626){ref-type="table-fn"},[b](#tfn27-etm-0-0-4626){ref-type="table-fn"}^    42.13±10.36^[a](#tfn26-etm-0-0-4626){ref-type="table-fn"},[b](#tfn27-etm-0-0-4626){ref-type="table-fn"}^   41.25±10.96^[a](#tfn26-etm-0-0-4626){ref-type="table-fn"},[b](#tfn27-etm-0-0-4626){ref-type="table-fn"}^   43.88±12.32^[a](#tfn26-etm-0-0-4626){ref-type="table-fn"},[b](#tfn27-etm-0-0-4626){ref-type="table-fn"}^   47.38±13.14^[a](#tfn26-etm-0-0-4626){ref-type="table-fn"},[b](#tfn27-etm-0-0-4626){ref-type="table-fn"}^
    200 mg/kg     35.00±6.19^[a](#tfn26-etm-0-0-4626){ref-type="table-fn"},[b](#tfn27-etm-0-0-4626){ref-type="table-fn"}^    38.00±11.16^[a](#tfn26-etm-0-0-4626){ref-type="table-fn"},[b](#tfn27-etm-0-0-4626){ref-type="table-fn"}^   34.50±10.38^[a](#tfn26-etm-0-0-4626){ref-type="table-fn"},[b](#tfn27-etm-0-0-4626){ref-type="table-fn"}^   36.38±10.25^[a](#tfn26-etm-0-0-4626){ref-type="table-fn"},[b](#tfn27-etm-0-0-4626){ref-type="table-fn"}^   42.38±11.67^[b](#tfn27-etm-0-0-4626){ref-type="table-fn"},[c](#tfn28-etm-0-0-4626){ref-type="table-fn"}^
    400 mg/kg     19.88±3.23^[b](#tfn27-etm-0-0-4626){ref-type="table-fn"},[c](#tfn28-etm-0-0-4626){ref-type="table-fn"}^    28.13±12.56^[a](#tfn26-etm-0-0-4626){ref-type="table-fn"},[b](#tfn27-etm-0-0-4626){ref-type="table-fn"}^   24.75±7.36^[b](#tfn27-etm-0-0-4626){ref-type="table-fn"}^                                                  27.88±10.37^[b](#tfn27-etm-0-0-4626){ref-type="table-fn"},[c](#tfn28-etm-0-0-4626){ref-type="table-fn"}^   32.75±12.83^[b](#tfn27-etm-0-0-4626){ref-type="table-fn"}^

Values are expressed as mean ± standard deviation (n=8).

P\<0.01 vs. intact control

P\<0.01 vs. UVB control

P\<0.05 vs. intact control. UVB, ultraviolet B; PARP, cleaved poly(ADP-ribose) polymerase; NT, nitrotyrosine; 4-HNE, 4-Hydroxynonenal; MMP, matrix metalloproteinase; PCP, dried pomegranate juice concentrated powder; PCS, pomegranate juice concentrated solution.

[^1]: Contributed equally
